Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:56:18.428Z.
Calculation as of: 2026-10-06T20:56:18.428Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26be04fabca1f5abb96b6b094ab833c4d2e2f23bc88365d6eea621c26c981704
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Corbus Pharmaceuticals Holdings, Inc.
Market Cap
$107.09M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.98M
Price/OCF Ratio
143.41
TTM Avg
45.05
3Y Avg
23.19
5Y Avg
15.20
Market Cap
$106.96M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.14M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.68M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.26M
Price/OCF Ratio
2.52
TTM Avg
3.01
3Y Avg
10.71
5Y Avg
28.96
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | $107.09M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $107.17M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 143.41 | 45.05 | 23.19 | 15.20 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | N/A | N/A | N/A | N/A |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $106.52M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | N/A | N/A | N/A | N/A |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 2.52 | 3.01 | 10.71 | 28.96 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
